Amphastar Pharmaceuticals, Inc. (AMPH) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↑
10.40
↓-12% vs avg
5yr avg: 11.83
30Y Low9.3·High96.8
P/FCF
↓
8.78
↓-47% vs avg
5yr avg: 16.68
30Y Low10.7·High50.9
P/B Ratio
↓
1.46
↓-51% vs avg
5yr avg: 2.96
30Y Low1.6·High5.1
ROE
↓
12.9%
↑-30% vs avg
5yr avg: 18.5%
30Y Low-4%·High24%
Debt/EBITDA
↑
4.40
↑+94% vs avg
5yr avg: 2.27
30Y Low0.8·High6.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AMPH Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Amphastar Pharmaceuticals, Inc. trades at 11.8x earnings, 30% below its 5-year average of 16.8x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 47%. On a free-cash-flow basis, the stock trades at 8.8x P/FCF, 47% below the 5-year average of 16.7x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $1.3B | $1.9B | $3.3B | $1.5B | $1.2B | $988M | $963M | $923M | $931M | $875M |
| Enterprise Value | $1.6B | $1.8B | $2.4B | $3.8B | $1.4B | $1.1B | $963M | $954M | $887M | $912M | $840M |
| P/E Ratio → | 11.77 | 13.19 | 12.13 | 23.79 | 16.10 | 18.63 | 703.15 | 19.68 | — | 213.78 | 83.73 |
| P/S Ratio | 1.48 | 1.79 | 2.64 | 5.09 | 2.94 | 2.65 | 2.82 | 2.99 | 3.13 | 3.87 | 3.43 |
| P/B Ratio | 1.46 | 1.64 | 2.64 | 5.13 | 2.78 | 2.60 | 2.20 | 2.25 | 2.53 | 2.76 | 2.66 |
| P/FCF | 8.78 | 10.65 | 11.22 | 22.56 | 22.55 | 16.44 | 42.20 | 4650.75 | — | 226.42 | 50.94 |
| P/OCF | 6.82 | 8.27 | 9.06 | 17.86 | 16.47 | 11.83 | 17.25 | 23.05 | 24.17 | 23.73 | 22.69 |
P/E links to full P/E history page with 30-year chart
AMPH EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Amphastar Pharmaceuticals, Inc.'s enterprise value stands at 10.4x EBITDA, 12% below its 5-year average of 11.8x. The Healthcare sector median is 14.1x, placing the stock at a 26% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.47 | 3.32 | 5.83 | 2.84 | 2.60 | 2.75 | 2.96 | 3.01 | 3.80 | 3.29 |
| EV / EBITDA | 10.40 | 11.92 | 9.26 | 15.74 | 10.43 | 11.80 | 26.64 | 45.24 | 112.40 | 61.16 | 27.78 |
| EV / EBIT | 11.04 | 11.92 | 11.05 | 18.93 | 12.01 | 13.38 | 192.08 | 15.80 | — | 439.59 | 52.62 |
| EV / FCF | — | 14.66 | 14.11 | 25.85 | 21.73 | 16.13 | 41.11 | 4607.64 | — | 221.93 | 48.92 |
AMPH Profitability
Margins and return-on-capital ratios measuring operating efficiency
Amphastar Pharmaceuticals, Inc. earns an operating margin of 19.5%. Operating margins have compressed from 30.6% to 19.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 12.9% is modest. ROIC of 8.4% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.5% | 49.5% | 51.1% | 54.5% | 49.9% | 45.6% | 41.0% | 40.9% | 36.3% | 37.8% | 40.8% |
| Operating Margin | 19.5% | 19.5% | 28.1% | 30.6% | 21.5% | 16.0% | 3.1% | -0.0% | -2.9% | -0.4% | 6.1% |
| Net Profit Margin | 13.6% | 13.6% | 21.8% | 21.3% | 18.3% | 14.2% | 0.4% | 15.2% | -1.9% | 1.9% | 4.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.9% | 12.9% | 23.3% | 23.6% | 18.8% | 13.9% | 0.3% | 12.4% | -1.6% | 1.4% | 3.4% |
| ROA | 6.1% | 6.1% | 10.3% | 12.2% | 12.9% | 9.5% | 0.2% | 8.9% | -1.2% | 1.0% | 2.6% |
| ROIC | 8.4% | 8.4% | 13.1% | 18.5% | 17.9% | 12.4% | 2.0% | -0.0% | -2.0% | -0.2% | 4.2% |
| ROCE | 9.8% | 9.8% | 15.3% | 20.4% | 17.7% | 12.9% | 2.2% | -0.0% | -2.2% | -0.2% | 4.5% |
AMPH Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Amphastar Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 4.4x, which is highly leveraged (35% above the sector average of 3.3x). Net debt stands at $486M ($656M total debt minus $170M cash). Interest coverage of 5.9x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.83 | 0.83 | 0.89 | 0.98 | 0.19 | 0.23 | 0.15 | 0.16 | 0.14 | 0.14 | 0.11 |
| Debt / EBITDA | 4.40 | 4.40 | 2.48 | 2.61 | 0.76 | 1.09 | 1.86 | 3.16 | 6.36 | 3.16 | 1.25 |
| Net Debt / Equity | — | 0.62 | 0.68 | 0.75 | -0.10 | -0.05 | -0.06 | -0.02 | -0.10 | -0.05 | -0.11 |
| Net Debt / EBITDA | 3.26 | 3.26 | 1.90 | 2.01 | -0.39 | -0.22 | -0.70 | -0.42 | -4.58 | -1.24 | -1.14 |
| Debt / FCF | — | 4.01 | 2.90 | 3.30 | -0.82 | -0.31 | -1.08 | -43.12 | — | -4.49 | -2.02 |
| Interest Coverage | 5.85 | 5.85 | 7.25 | 7.31 | 63.86 | 96.07 | 13.40 | 507.12 | -39.85 | 2.51 | 15.60 |
AMPH Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Amphastar Pharmaceuticals, Inc.'s current ratio of 4.02x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.90x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 2.17x to 4.02x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.02 | 4.02 | 3.07 | 2.17 | 3.99 | 3.06 | 2.49 | 2.84 | 2.06 | 2.79 | 3.04 |
| Quick Ratio | 2.90 | 2.90 | 2.19 | 1.70 | 2.90 | 2.17 | 1.63 | 1.61 | 1.41 | 1.85 | 1.72 |
| Cash Ratio | 1.79 | 1.79 | 1.28 | 1.14 | 1.85 | 1.32 | 0.94 | 0.99 | 0.83 | 1.02 | 1.20 |
| Asset Turnover | — | 0.44 | 0.46 | 0.43 | 0.67 | 0.65 | 0.55 | 0.55 | 0.57 | 0.53 | 0.60 |
| Inventory Turnover | 2.06 | 2.06 | 2.33 | 2.77 | 2.41 | 2.56 | 2.13 | 1.72 | 2.71 | 2.35 | 1.89 |
| Days Sales Outstanding | — | 72.79 | 68.83 | 65.40 | 64.96 | 65.70 | 68.86 | 51.38 | 64.61 | 54.70 | 38.30 |
AMPH Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Amphastar Pharmaceuticals, Inc. returns 7.1% to shareholders annually primarily through share buybacks. The earnings yield of 8.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 8.5% | 7.6% | 8.2% | 4.2% | 6.2% | 5.4% | 0.1% | 5.1% | — | 0.5% | 1.2% |
| FCF Yield | 11.4% | 9.4% | 8.9% | 4.4% | 4.4% | 6.1% | 2.4% | 0.0% | — | 0.4% | 2.0% |
| Buyback Yield | 7.1% | 5.9% | 4.4% | 1.8% | 2.7% | 2.5% | 2.5% | 2.3% | 2.7% | 3.3% | 1.1% |
| Total Shareholder Yield | 7.1% | 5.9% | 4.4% | 1.8% | 2.7% | 2.5% | 2.5% | 2.3% | 2.7% | 3.3% | 1.1% |
| Shares Outstanding | — | $48M | $52M | $53M | $52M | $50M | $49M | $50M | $46M | $48M | $48M |
Peer Comparison
Compare AMPH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AMPHYou | $1B | 11.8 | 10.4 | 8.8 | 49.5% | 19.5% | 12.9% | 8.4% | 4.4 |
 LNTH | $6B | 25.3 | 13.8 | 15.8 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 PCRX | $932M | 148.1 | 9.9 | 6.8 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 PRGO | $2B | -1.2 | 7.5 | 11.6 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 AKRO | $4B | -14.6 | — | — | — | — | -39.2% | -55.3% | — |
 SUPN | $3B | -75.7 | 52.6 | 64.4 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 AKBA | $393M | -74.0 | 8.9 | 5.8 | 83.3% | 9.9% | -16.4% | — | — |
 MNKD | $1B | 178.0 | 29.3 | 80.3 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 NKTR | $2B | -8.7 | — | — | — | -253.7% | -217.9% | -75.2% | — |
 MCK | $91B | 28.9 | 18.5 | 17.4 | 3.5% | 1.2% | — | 540.6% | 1.5 |
 CAH | $45B | 29.7 | 16.5 | 24.4 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See AMPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AMPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AMPH vs LNTH
Side-by-side business, growth, and profitability comparison vs Lantheus Holdings, Inc..
Start ComparisonAMPH — Frequently Asked Questions
Quick answers to the most common questions about buying AMPH stock.
What is Amphastar Pharmaceuticals, Inc.'s P/E ratio?
Amphastar Pharmaceuticals, Inc.'s current P/E ratio is 11.8x. The historical average is 26.8x.
What is Amphastar Pharmaceuticals, Inc.'s EV/EBITDA?
Amphastar Pharmaceuticals, Inc.'s current EV/EBITDA is 10.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 31.7x.
What is Amphastar Pharmaceuticals, Inc.'s ROE?
Amphastar Pharmaceuticals, Inc.'s return on equity (ROE) is 12.9%. The historical average is 8.3%.
Is AMPH stock overvalued?
Based on historical data, Amphastar Pharmaceuticals, Inc. is trading at a P/E of 11.8x. Compare with industry peers and growth rates for a complete picture.
What are Amphastar Pharmaceuticals, Inc.'s profit margins?
Amphastar Pharmaceuticals, Inc. has 49.5% gross margin and 19.5% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Amphastar Pharmaceuticals, Inc. have?
Amphastar Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 4.4x, indicating high leverage. A ratio above 4x may signal elevated financial risk.